PDAC is a highly aggressive malignant cancer and the 3rd leading cause of cancer related deaths in the US. The aggressive nature of PDAC is in part due to the desmoplastic tumor microenvironment, which promotes rapid tumor growth and impedes therapeutic efficacy of conventional therapies. Immune checkpoint inhibitors have showed specific efficacy in PDAC promotes extracellular remodeling for effective treatment of aggressive tumors. In this study we investigated the ability of an MR molecular imaging technology for image guidance and therapeutic monitoring of PD-L1 treated PDAC tumors.
No takes yet. Share an insight, caveat, or question.
Laney et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: